We are building a Global Leader in the field of Repurposing Drugs for Orphan Diseases.
Our mission is to discover drugs for high unmet medical needs that will improve quality of life for patients with Rare Diseases.
We stand out by our ability to deliver high value products with relatively little cost in a short period of time, due to our model we reduce the risk of drug development.
SOM Biotech has a strong pipeline of products focused on CNS at preclinical and clinical stages.
NEWS & PRESS RELEASES
SOM Biotech licenses its first product and expands to the United States
The med-tech biopharmaceutical company SOM Biotech, specializing in repurposing drugs to treat rare nervous system […]
SOM Biotech at the 2017 New York Venture Summit
SOM Biotech has been selected to present at the 2017 New York Venture Summit in […]
21st Summer School of the University of Barcelona
SOM Biotech has been invited to make a Lecture on “Drug Repurposing in rare diseases” […]
9th Summer School on Medicines
Dr. Raúl Insa, SOM Biotech CEO, will be the speaker at Closing Session of 9th […]
SOM Biotech closed €2M funding round and opens €10M Series A
SOM Biotech closed €2M funding round on January 2017 where 18 international investors from 10 […]
SOM Biotech at World Orphan Drug Congress USA 2017
SOM Biotech attended the World Orphan Drug Congress USA 2017 (WODC) hold in Washington, USA […]
SOM Biotech will be attending next BIO Convention 2017
SOM Biotech will be attending BIO Convention on June 19th-22nd 2017 in San Diego. Michael […]
SOM Biotech will take part in the EU Compass program for RRI
SOM Biotech will be one of the companies participating in the EU Compass program, Biomedicine […]
SOM Biotech announces a worldwide license with Corino Therapeutics, Inc. for SOM0226, a drug for the treatment of TTR Amyloidosis.
SOM Biotech Ltd (SOM) a leading clinical-stage biopharmaceutical company specialized in drug repurposing to treat […]
SOM Biotech SL Announces New Logo and Website Launch
The new and completely redesigned website offers quick and easy access to essential and relevant […]